Oppenheimer raised the firm’s price target on Neurocrine to $165 from $160 and keeps an Outperform rating on the shares. The Phase 3 CAHtalyst study of crinecerfont in pediatric CAH patients met primary and key secondary endpoints with overwhelming statistical significance, and the firm believes crinecerfont provides an important opportunity for Neurocrine to demonstrate successful clinical development, regulatory and commercial capabilities on a global scale, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine Stock (NASDAQ:NBIX) Gains on Positive Pediatric Phase 3 Results
- Neurocrine’s crinecerfont meets primary and secondary endpoints in Phase 3 trial
- Neurocrine participates in a conference call with William Blair
- Neurocrine price target raised to $135 from $125 at Barclays
- Neurocrine presenting post hoc data analysis in congenital adrenal hyperplasia